TRiCares Secures $50 Million Series D Financing for Clinical Advancements

TRiCares, a portfolio company of Andera Partners, has successfully raised $50 million in Series D financing. This investment will predominantly fund upcoming clinical milestones for TRiCares' transfemoral tricuspid heart valve replacement system, Topaz, in both the US and EU markets.

The financing round, backed by a single strategic investor, will enable the completion of an Early Feasibility Study (EFS) in the US, initiate a pivotal trial in Europe, and advance the development of additional valve sizes and next-generation delivery systems for Topaz.

Andera Partners and other leading European life science venture capital firms have been investors in TRiCares since 2018. TRiCares has already secured Investigational Device Exemption (IDE) for its EFS from the US FDA, with plans to enroll patients at multiple sites across the US and Canada in the coming months.